Worldwide Plasma Therapy Market to Grow at 14% CAGR through 2021, Informs M&M in Its New Report Available at

05 Aug 2016 • by Natalie Aster

LONDON – By 2021, the global therapy market value is likely to increase from USD 135.6 million in the current year to over USD 297 million in 2021, witnessing a CAGR of 14% in the years to come. The pure platelet-rich plasma (PRP) segment is expected to see the highest CAGR through 2021, spurred by a range of factors including high performance of pure therapy, faster recovery and enhanced expenditures on health worldwide. 

Regionally, North America dominates the global plasma therapy market, with Europe and APAC following it. The top factors propelling growth in this regional market include manifold trauma incidents, rising spending on healthcare and medical insurance in the USA. However, the market growth may be slowed down by severe regulatory policies and bad effects caused by PRP therapy.

New topical research report “Plasma Therapy Market” recently worked out by MarketsandMarkets (M&M) offers a comprehensive analysis of the world’s plasma therapy market, covers growth strategies adopted by industry players and explores the competitive scenario in the market. Such top market players as BioLife Plasma Services, Cambryn Biologics, Biotest, Grifols International, Kedrion, LFB, Bio Products Laboratory, China Biologic Products and Octapharma are profiled in this report. Future growth prospects for the global plasma therapy market up to 2021 are outlined in this report.

For more new comprehensive reports by the publisher, please, follow to MarketsandMarkets’ catalogue available at


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970